Gilead Sciences Inc. (NASDAQ:GILD) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Gilead Sciences Inc. (NASDAQ:GILD) is one of the most profitable value stocks to buy right now. On April 7, Gilead Sciences announced its agreement to acquire Germany-based Tubulis GmbH for up to $5 billion. This transaction includes an upfront cash payment of $3.15 billion, with an additional $1.85 billion contingent on the achievement of specific milestones. This acquisition is part of a broader effort by Gilead to support its oncology pipeline as it faces declining sales of its COVID-19 treatment, Veklury, and looming patent expiries on other key products.
Through this deal, Gilead gains access to Tubulis’ portfolio of guided missiles, scientifically known as antibody-drug conjugates/ADCs. These experimental cancer treatments are designed to deliver chemotherapy directly to malignant cells, thereby minimizing damage to healthy tissue and reducing side effects. This move follows other recent high-value acquisitions, including the $7.8 billion purchase of Arcellx in February and the $2 billion acquisition of Ouro Medicines in March, as Gilead pivots toward high-growth areas like cancer and immune disorder treatments.
The acquisition reflects a continuing spree of deal-making intended to transform Gilead beyond its traditional dominance in virology. By integrating Tubulis’ ADC platform, Gilead Sciences Inc. (NASDAQ:GILD) aims to strengthen its position in the competitive oncology market. This investment aligns with the company’s recent history of aggressive expansion into cell therapy and precision medicine to secure long-term revenue streams in the face of shifting market dynamics.
Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.
While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.